To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health National Heart, Lung, and Blood Institute for fiscal year 2024.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
67pct
9d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
This bill limits FY2024 funding for the National Heart, Lung, and Blood Institute.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2023 · second_quarter · Medicare/Medicaid
S 4101 Preserving Patient Access to Home Infusion Act (all sections of full text)(support) HR 1976 Preserving Patient Access to Home Infusion Act (all sections of full text)(support) Discussions involving funding for state Medicaid programs to improve home- and community-based services Discussions involving federal definition of Long-Term Care pharmacies Discussions involving CMS finalized physician fee schedule Discussions involving home health Monitored discussions pertaining to proposed legislation regarding Pharmacy Benefit Managers Monitored discussions involving Medicare prescription drug proposals Monitored discussions involving hospice proposals
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
S 4204 and HR 1976, Medicare for All, private equity in health care, Oversight of private equity in health care, Healthcare Ownership Transparency Act.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| FL |
| Matthew M. Rosendale, Sr. | Republican | MT |